Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Zomedica in April?

By David Jagielski - Apr 14, 2021 at 6:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock has been falling sharply in the past month.

Zomedica (ZOM -5.59%) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision. 

Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio. 

Veterinarian treating a dog.

Image source: Getty Images.

Why are investors so bullish on Zomedica?

Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.

The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.

Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.

The big risk with Zomedica

Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.

Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.

But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.

There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.

Is Zomedica worth the risk?

It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.

You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.

In just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
ZOM
$0.21 (-5.59%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.